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Abstract
Background: Candidiasis is commonly observed in patients with primary sclerosing cholangitis (PSC), but the
clinical risk factors associated with its presence have not been fully investigated. In this study, we aimed to analyse
the incidence, risk factors, and transplantation-free survival in primary sclerosing cholangitis (PSC) patients with
persistent biliary candidiasis.
Methods: We retrospectively analysed patients diagnosed with PSC who were admitted to our department during
2002 to 2012. One-hundred fifty patients whose bile cultures were tested for fungal species were selected, and their
clinical and laboratory parameters were investigated. The results of endoscopic retrograde cholangiography (ERC)
and bile cultures were analysed using chart reviews. The cases of biliary candidiasis were sub-classified as transient
or persistent.
Results: Thirty out of 150 (20.0%) patients had biliary candidiasis. Although all patients demonstrated comparable
baseline characteristics, those with biliary candidiasis showed significantly reduced transplantation-free survival
(p < 0.0001) along with a markedly elevated frequency of cholangiocarcinoma (CCA) (p = 0.04). The patients were
further sub-classified according to the transient (15/30) or persistent (15/30) nature of their biliary candidiasis. A
subgroup analysis showed reduced survival with a greater necessity for orthotopic liver transplantation (OLT) only
in patients with persistence of Candida (p = 0.007). The survival in the patients with transient biliary candidiasis was
comparable to that in candidiasis-free patients. In a multivariate regression analysis that included Mayo risk score
(MRS), sex, age, dominant stenosis, inflammatory bowel disease, autoimmune hepatitis overlap syndrome, and
number of times ERC was performed, biliary candidiasis was an independent risk factor for reduced survival
(p = 0.008). Risk factors associated with acquisition of biliary candidiasis were age at PSC diagnosis and number
of ERCs.
Conclusions: The persistence of biliary candidiasis is associated with markedly reduced transplantation-free survival in
PSC patients. By contrast, actuarial survival in patients with transient biliary candidiasis approaches that for patients
without any evidence of biliary candidiasis. Further studies on the treatment of persistent biliary candidiasis in patients
with PSC are warranted.
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Background
Primary sclerosing cholangitis (PSC) is a chronic chole-
static liver disease characterized by inflammation and
stricture formation of the intra- and extrahepatic biliary
system, which progresses to liver cirrhosis in the ma-
jority of cases [1-3]. There is a strong association with
inflammatory bowel disease (IBD) in about 75% of pa-
tients, and a clear male predominance [4].
Therapeutic options for this condition are limited, and
although the data regarding the survival benefits of urso-
deoxycholic acid treatment are conflicting [5-8], it re-
mains the most frequently used therapeutic agent. In
end-stage disease, liver transplantation is the only cura-
tive therapy, and PSC remains a leading cause of liver
transplantation, despite its low prevalence in Western
countries [9]. The average time from first diagnosis to
liver transplantation is about 12 to 15 years [10]. Un-
fortunately, the pathogenesis of PSC is still unresolved.
Recent studies highlighted the influence of numerous
genetic risk factors [11-13], and it is well accepted that
immunological and environmental factors, such as trans-
mission of bacterial pathogens from the gut due to in-
creased permeability of the portal venous system, are
also involved [14-16].
Owing to the limited medical treatment options, cli-
nical management of PSC patients remains challenging,
and identification of high-risk patients is an important
problem for clinicians. Several clinical risk factors have
been described that are associated with the reduced
transplantation-free survival, e.g. dominant strictures
and concomitant immunological diseases or biliary in-
fections [17-19]. In addition to bacterial infections, some
studies suggested a strong influence of fungal infections
on the survival of PSC patients [20,21]. Up to now, only
Candida species have been described to cause fungal in-
fections in PSC patients. It is well known that Candida
species are frequently detected, especially in the pre-
sence of high-grade biliary strictures or tumour stenosis
[22]. Treatment of fungal infection is difficult, and in
many cases, eradication cannot be achieved [23].
In this study, we aimed to analyse clinical risk factors
associated with the presence of biliary candidiasis in
PSC patients. Furthermore, we sought to determine
the influence of persistent candidiasis, compared with
transient candidiasis, and to investigate its impact on
survival.
Methods
Patients and study design
This study was designed to analyse clinical risk factors
that are associated with biliary candidiasis and to assess
how the outcome is influenced by the presence of tran-
sient and persistent biliary candidiasis. We screened all
the PSC patients who were treated at the Heidelberg
University Hospital between January 2002 and October
2012. During the study period, 290 PSC patients visited
our department. The diagnosis of PSC was established
on the basis of typical endoscopic retrograde cholan-
giography (ERC) findings, serum alkaline phosphatase
activity of at least twice the reference range, negative
antimitochondrial antibody, and results of liver biopsy
compatible with the diagnosis of PSC. Only the patients
with available results of endoscopic treatment and bile
culture tests for fungal species were included in the final
analysis. A total of 150 patients that satisfied the above se-
lection criteria were followed until January 2013 (Table 1);
Ninety-nine of the patients were diagnosed with PSC du-
ring their first ERC, performed in our department. Of the
other 51 patients, 34 had dominant strictures treated by
dilatation therapy before visiting our tertiary center. The
frequency of strictures, numbers of bile cultures, and fre-
quency of biliary candidiasis were not different between
patients with their first ERC performed in our department
and patients treated endoscopically prior to their first visit
to our institution. 136 patients were excluded due to miss-
ing bile cultures tests for fungal infection. Four patients,
diagnosed with CCA their first visit at our departement,
were excluded because biliary candida was only detected
after chemotherapy. The excluded patients showed a
lower frequency of dominant stenosis and a trend for
longer survival compared with our study cohort (log-rank,
p = 0.1). The male/female ratio and the frequencies of
Table 1 Baseline characteristics of the patients
N (%) or
mean ± SD
Reference
value
Patients 150
Age at diagnosis (years) 32.0 ± 1.0
Male sex 108 (72.0)
IBD 108 (72.0)
Overlap with autoimmune hepatitis 13 (8.7)
Dominant stenosis 100 (66.7)
Dominant stenosis at first diagnosis 22 (14.7)
Number of ERCs 618
Number of ERCs per patient 3.0 ± 0.3
Laboratory parameters at baseline
Bilirubin (mg/dL) 0.9 ± 0.3 −1.1
ALT (IU/L) 92.5 ± 9.6 −23
AST (IU/L) 63.7 ± 6.2 −19
AP (IU/L) 252.1 ± 20.2 −175
GGT (IU/L) 267.0 ± 28.5 −60
Albumin (g/dL) 42.0 ± 0.5 35–55
Mayo risk score −0.12 ± 0.1
IBD, inflammatory bowel disease; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; AP, alkaline phosphate; GGT, γ-glutamyltransferase; ERC,
endoscopic retrograde cholangiography.
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CCA, liver transplantation, and death were not different
between the study cohort and the excluded patients.
Despite a lower level of alkaline phosphatase in our study
cohort, compared with the excluded patients, there were
no differences in baseline laboratory parameters, or in
Mayo Risk Score, at baseline. The treatment of CCA in-
volved liver transplantation for local disease (according to
the Mayo-protocol) or partial liver resection. In advanced
disease, chemotherapy was administered.
Definitions
Transient candidiasis was defined as at least one bile cul-
ture positive for Candida sp., followed by at least one bile
culture negative for biliary Candida and consecutive nega-
tive bile cultures until the end of the study. Persistent can-
didiasis was defined as bile cultures positive for Candida
sp. until the end of study. Dominant stenosis was defined
as a stenosis with a diameter smaller than 1.5-mm for the
common duct or smaller than 1.0-mm in case of a hepatic
duct (within 2 cm of the bifurcation). In patients with total
or subtotal stenosis of the major duct, balloon dilatation
of the stenosis was performed. Brush cytology was per-
formed routinely in patients with an initial diagnosis of
strictures during ERC and, furthermore, in any patient
with suspected malignant disease. The end point was
defined as liver transplantation or death.
Antibiotic and antifungal treatment
For prevention of bacterial cholangitis as a consequence
of ERC, the patients received peri-interventional antibiotic
prophylaxis (mezlocillin or ciprofloxacin). The patients
were not administered antibiotics before endoscopy, but
received them intravenously directly after the aspiration of
the bile sample and 1 week after the treatment. The pa-
tients with pre-existing bacterial cholangitis received
intravenous mezlocillin, which was replaced with cipro-
floxacin in patients with known allergy to penicillin, or
further adapted according to an antibiogram.
Antifungal treatment was conducted for 8 out of 30
patients with Candida spp. present in the bile and who
had clinical signs of cholangitis. Five patients were
treated with fluconazole, two were treated with caspo-
fungin, and one patient received voriconazole. Six out of
8 treated patients also had dominant stenosis. The pa-
tients without clinical signs of cholangitis and biliary
candidiasis were not treated with specific antifungal
agents because such a general recommendation did not
exist at the time of the study.
Bile cultures
All bile samples were obtained after selective bile duct in-
tubation. Utilization of this method made contamination
from the intestine unlikely. For all the patients, ERC was
performed by an experienced gastroenterologist. Aliquots
of all biliary samples were placed in sterile tubes and deliv-
ered to the microbiology laboratory within 2 hours. The
samples were cultured aerobically at 37 °C for 48 hours on
blood plates (Colombia agar with 5% sheep blood), cho-
colate agar, and CHROMagar™ Candida medium (all from
Becton-Dickinson, Franklin Lakes, NJ, USA), as well as
anaerobically using Schaedler agar (5% sheep blood, bio-
Merieux, Marcy l’Etoile, France). The cultures were incu-
bated for 48 hours, with the first reading taken after
24 hours.
Statistical analysis
Calculations were carried out using PASW Statistics 20.
Frequencies were compared using a chi-square test.
Continuous data were compared using the nonpara-
metric Wilcoxon rank-sum test or the Fisher’s exact test,
where appropriate. Actuarial transplantation-free sur-
vival was estimated using a Kaplan-Meier product limit
estimator. Differences between the actuarial estimates
were tested using the log rank test. Factors that inde-
pendently affected the risk of reduced transplantation-
free survival were determined using Cox proportional
hazard ratio models with simultaneous adjustment for
Mayo risk score, sex, age at first diagnosis, presence of
IBD, presence of dominant stenosis, concomitant auto-
immune hepatitis overlap syndrome, number of ERCs,
and biliary candidiasis. Furthermore, we used Cox pro-
portional hazard ratio models to explore the relative
risks of biliary candidiasis with regard to clinical risk fac-
tors such as sex, age at diagnosis of PSC, presence of
dominant stenosis, presence of IBD, Mayo risk score,
and number of ERCs; p-values < 0.05 were considered
statistically significant.
Informed consent
Written informed consent was obtained from each pa-
tient, and the study protocol conformed to the ethical
guidelines of the Declaration of Helsinki in its current
version, as reflected in a priori approval by the institu-
tion’s human research review committee. The study was
approved by the local ethics committee of Heidelberg
University.
Results
Clinical and laboratory characteristics at baseline
A cohort of 150 patients with PSC was analysed in this
study. One hundred eight (72.0%) patients were men
and 42 (28.0%) were women. One hundred eight (72.0%)
patients had concomitant IBD and 100 (66.7%) showed
dominant stenosis. Of the patients with dominant ste-
nosis, 22 (14.7%) displayed this during their initial PSC
diagnosis and 78 (52.0%) developed dominant stenosis
during the course of their disease. The median age of
diagnosis was 32.0 years. Other clinical and laboratory
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baseline characteristics are summarized in Table 1. Bile cul-
tures were routinely collected from all the patients during
ERC and tested for the presence of bacterial and fungal spe-
cies. On average 3.0 ± 0.3 (median ± SEM) bile cultures
were collected for each patient. Bacterial strains were iden-
tified in bile cultures of 105 (70.0%) patients. involving
Enterococcus sp., in the majority of cases. One hundred
twenty (80.0%) patients had no evidence of biliary candidia-
sis throughout the course of the study, whereas 30 (20.0%)
patients had at least one bile culture positive for Candida
spp.; C. albicans was detected in 25 patients, C. glabrata
was identified in three patients; both C. kruzei and C. spher-
ica were detected in one patient, and both C.kruzei and
C. albicans were found in one patient. In five of those pa-
tients, only Candida sp. were identified during the course
of disease. Six patients had candida identified in their initial
bile culture. All of these patients had their first ERC in our
department. In five other patients, the candida were biliary
pathogens that were first identified after a prior, sterile bile
culture. Four additional patients did not have antibiotic
treatment prior to detection of biliary candidiasis. The re-
maining fifteen patients had endoscopic treatment and anti-
biotic therapy due to dominant stenosis and episodes of
cholangitis. None of the patients included in the study
received long-term antibiotic therapy. The patients were
further sub-classified according to the transient (n = 15) or
persistent (n = 15) nature of candidiasis (Figure 1).
Clinical characteristics and clinical course with regard to
the presence of biliary candidiasis
Although there were no significant differences in the base-
line clinical and laboratory parameters between the pa-
tients with Candida-positive and Candida-negative bile
cultures, except for elevated levels of γ-glutamyltransferase
(p = 0.05) at inclusion into the study, such differences were
found when the sub-division of candidiasis into transient
and persistent forms was taken into account. Only the
patients with the transient form showed elevated levels of
γ-glutamyltransferase compared to that of the patients
without candidiasis (p = 0.01). Furthermore, the patients
with persistent candidiasis had higher albumin levels at
baseline than the individuals without candidiasis (p = 0.04).
The other clinical and laboratory parameters did not vary
between the subgroups. We further analysed the clinical
course of the patients with regard to the presence and per-
sistence of biliary Candida. Although the frequency of
dominant stenosis was similar between the subgroups, the
patients with persistent candidiasis developed re-stenosis
of the large bile ducts significantly more often than the pa-
tients with transient candidiasis (14/15 vs. 9/15; p = 0.031).
The frequency of dominant stenosis at the initial PSC
diagnosis and at subsequent time points were not different
between the subgroups (Table 2). Eight patients received
specific antifungal treatment, including five treated with
fluconazole, two with caspofungin, and one with voricona-
zole. Of those patients, one fluconazole-treated patient,
both caspofungin-treated patients, and the patient re-
ceiving voriconazole achieved clearance of the candida
from their bile fluid. Candida treatment was not associated
with eradication of biliary candidiasis (4/15 vs. 4/15,
p = 1.0) or improved transplantation-free survival (mean:
14.3 ± 1.5 years vs. 13.8 ± 4.3 years; p = 0.9) (Table 3).
Outcome analysis
The patients with bile cultures positive for Candida
showed a markedly elevated frequency of CCA (p = 0.04),
although there was no difference between the 2 subgroups.
The mean time interval between detection of Candida in
the bile and CCA diagnosis was 2.2 years. Of note, three of
the five patients with CCA were diagnosed with candidia-
sis at the same time as their initial CCA diagnosis. Patients
with candidiasis needed orthotopic liver transplantation
(OLT) more often, and they more often reached the
combined endpoint (OLT: p = 0.007; death/OLT combined:
p < 0.0001). All patients died due to CCA. A subgroup
analysis revealed elevated frequencies of OLT and reaching
the combined endpoint only in the patients with persistent
candidiasis (p = 0.003 and p = 0.004, respectively) (Table 2).
These results were confirmed by Kaplan-Meier analysis.
The patients with candidiasis showed a markedly reduced
transplantation-free survival than those without Candida
(log-rank: p < 0.001). Remarkably, only the patients with
persistent candidiasis showed reduced transplantation-free
survival (log-rank: p = 0.002) (Figure 2A-C).
Assessment of risk factors for reduced transplantation-free
survival and biliary candidiasis
In order to identify clinical risk factors for acquisition
of biliary candidiasis, we performed univariate and
150 PSC patients
Candida positive
bile culture (n=30)
Candida negative
bile culture (n=120)
Biliary candida
eradication (n=15)
No Biliary candida
eradication (n=15)
Figure 1 Schematic representation of the study design.
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multivariate Cox regression analyses. We included the fol-
lowing potential risk factors: sex, presence of dominant
stenosis, presence of IBD, autoimmune hepatitis overlap
syndrome, age at diagnosis of PSC, number of ERCs, and
Mayo risk score at baseline. In the univariate regression
analysis, the presence of dominant stenosis (p = 0.05), age
at diagnosis (p = 0.02), and number of ERCs (p = 0.002)
were associated with biliary candidiasis. In the multivariate
analysis, only age at diagnosis (p = 0.019) and number
of ERCs (p = 0.025) were independently associated with
biliary candidiasis (Table 4).
Finally, we evaluated the influence of the same clinical
risk factors together with the presence of biliary candidiasis
on actuarial transplantation-free survival in our study co-
hort. In the univariate analysis, Mayo risk score (p = 0.02)
and biliary candidiasis (p = 0.006) were associated with
Table 2 Clinical characteristics with regard to the presence of Candida in the bile fluid
No Candida Candida Transient Candida Persistent Candida Reference value
Patients 120 30 15 15
Age at diagnosis (years) 32.0 ± 1.1* 31.0 ± 2.3 37.0 ± 3.6 27.0 ± 2.9
Male sex 87 (72.5) 21 (70.0) 9 (60.0) 12 (80.0)
IBD 86 (71.7) 22 (73.3) 10 (66.7) 12 (80.0)
Overlap with autoimmune hepatitis 11 (9.2) 2 (6.7) 2 (13.3) 0 (0.0)
Dominant stenosis 76 (63.3) 24 (80.0) 11 (86.7) 13 (73.3)
- at first diagnosis 17 (14.2) 5 (16.7) 2 (13.3) 3 (20.0)
- time from first diagnosis, years 5.9 ± 5.7 5.6 ± 4.5 5.6 ± 4.9 5.6 ± 4.4
Number of ERCs per patient 3.0 ± 0.3 4.0 ± 0.6 4.0 ± 0.7 4.0 ± 1.0
Laboratory parameters at baseline
Bilirubin (mg/dL) 0.9 ± 0.3 0.9 ± 0.9 1.0 ± 0.7 0.8 ± 1.6 −1.1
ALT (IU/L) 88.7 ± 10.5 118.0 ± 23.2 104.6 ± 45.6 124 ± 12.8 −23
AST (IU/L) 53.9 ± 6.2 82.0 ± 18.3 90.4 ± 24.4 70.0 ± 28.1 −19
AP (IU/L) 240.4 ± 23.0 266.5 ± 41.6 270.0 ± 80.0 265.0 ± 24.3 −175
GGT (IU/L) 247.5 ± 31.1 344.5 ± 67.7a 448.0 ± 112.9a 279 ± 62.6 −60
Albumin (g/dL) 41.0 ± 0.6 45.0 ± 1.5 41.0 ± 2.7 45.0 ± 1.3a 35–55
Mayo Risk Score −0.25 ± 0.1 −0.28 ± 0.3 0.04 ± 0.3 −0.3 ± 0.4
Clinical outcome
Development of CCA 6 (5.0) 5 (16.7)a 4 (26.7)a 1 (6.7)
Death 8 (6.7) 4 (13.3) 3 (20.0) 1 (6.7)
OLT 20 (16.8) 14 (46.7)a 5 (33.3) 9 (60.0)a
Death/OLT 28 (23.3) 18 (60.0)a 8 (53.3) 10 (66.7)a
Survival free of liver transplantation (years) 20.1 ± 2.1 11.5 ± 2.6a 17.8 ± 7.3 11.1 ± 2.1a
IBD, inflammatory bowel disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AP, alkaline phosphate; GGT, γ-glutamyltransferase;
ERC, endoscopic retrograde cholangiography; OLT, orthotopic liver transplantation; CCA, cholangiocarcinoma.
*Data are presented as N (%) or mean ± SD.
aSignificantly different from patients without candida (p <0.05).
Table 3 Characteristics associated with identification of specific fungal species; all values represent N
C. albicans C. glabrata C. kruzei C. tropicalis C. spherica
Patients 25 3 2* 1 1
Candida only 4 0 1* 1 0
Additional bacteria in bile 21 3 1 0 1
Dominant stenosis 20 2 2 1 1
Dominant stenosis at first diagnosis 5 0 0 0 0
Cholangiocarcinoma 5 0 1* 0 1
Anti-fungal treatment 7 1 0 0 0
Clearance of candidiasis 3 1 0 0 0
*In one patient C. kruzei and C. tropicalis were concomitantly detected. In another patient C. kruzei and C. spherica were concomitantly detected.
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reduced survival, whereas presence of dominant stenosis
and IBD reached borderline significance. In the multiva-
riate analysis, presence of dominant stenosis (p =0.04),
presence of IBD (p = 0.02), Mayo risk score (p = 0.01), and
biliary candidiasis (p = 0.008) were independently asso-
ciated with reduced survival (Table 5).
Discussion
In this large PSC cohort, we were able to identify clinical
risk factors associated with acquisition of biliary candid-
iasis. Furthermore, we validated the negative influence of
biliary candidiasis in PSC patients. This effect was espe-
cially emphasised in the patients with persistence of
biliary candida throughout the course of the disease,
whereas eradication of candida from the bile fluid resulted
in survival rates almost comparable to those of patients
without biliary candidiasis. Successful dilatation of biliary
obstructions may contribute to candida eradication.
Several studies demonstrated that pathogenic antigens
infiltrating the liver are capable of inducing hepatobiliary
inflammation with numerous features of PSC. In particu-
lar, the increased enterohepatic circulation of pathogenic
antigens as a consequence of abnormal intestinal per-
meability can contribute to the pathogenesis of PSC
[15,24,25]. In this regard, portal bacteremia and bactero-
bilia were demonstrated in PSC patients with concomitant
IBD [26]. Several studies of antibiotic treatment of PSC
provided evidence for a beneficial effect on biochemical
parameters and the resolution of symptoms [27]. Chronic
alterations in the composition of the microbiome were
shown to contribute to the pathogenesis of IBD and may
also play a pivotal role in PSC [28].
In addition to bacterial infections common for PSC,
fungal infections are becoming an increasingly recognized
complication associated with a poor prognosis. The
frequency of fungal pathogens in the bile fluid ranges from
15 to 50%, depending on the underlying disease
[19,22,29]. The persistence of candida has already been as-
sociated with a worse prognosis in neonates [30]. In this
study, we were able to detect Candida sp. in 20% of all
patients. Furthermore, these patients showed markedly re-
duced transplantation-free survival when compared to the
patients without candidiasis. Similar results have been de-
scribed before, especially in immunosuppressed patients,
after liver transplantation or with haematological malig-
nancies [31-33]. Importantly, in the eight patients under-
going concomitant blood and bile cultures, Candida spp.
were not detected in any blood cultures; underscoring the
importance of standardized bile culture sampling [34]. In
our study cohort, C. albicans was the most frequent fungal
species isolated, detectable in 25 of 30 patients. If non-
albicans species were excluded from the survival analysis,
the results become even more significant, indicating a
pathogenetic role for C. albicans. Of note, the negative
Figure 2 Kaplan–Meier analysis of actuarial transplantation-free
survival (n = 150). The survival is given in years from the time of
first diagnosis. Patients with biliary candidiasis had reduced survival
compared to patients without candidiasis (A). Patients with transient
biliary candidiasis showed no difference in survival rates (B), whereas
patients with persistent biliary candidiasis had markedly reduced
survival (C).
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effect of candida on survival in our cohort was indepen-
dent of the number of interventions, although the number
of interventions was a risk factor for the acquisition of bil-
iary fungal infections. The negative effect of candidiasis
was also independent of dominant stenosis, indicating that
the pathological effect of candidiasis is likely independent
of biliary obstructions caused by dominant stenosis. In
line with this finding, dilatation therapy for dominant
stenosis was more successful in patients with the transient
form of candidiasis, and there was less need to repeat the
endoscopic therapy. Therefore, the persistence of Candida
species may be, in part, explained by the impaired biliary
clearance in patients with persistent biliary candidiasis
[35], but may also be an indication of compromised host
defence [33,36,37]. Importantly, this condition seems to
be resolved by liver transplantation, as only two out of
fourteen patients had evidence of candida in their bile
fluid after liver transplantation.
Clinical risk factors associated with the acquisition of
biliary fungal infections are important for reasonable
and cost effective screening strategies. Our analysis iden-
tified repeated therapeutic endoscopic interventions as
well as older age at the time of diagnosis as independent
risk factors associated with biliary candidiasis. Import-
antly, diagnostic ERCs do not confer an increased risk of
biliary fungal infections in our cohort, as also been
shown by other groups [22].
The interpretation of our results is limited by the
retrospective nature of the study and the lack of a con-
sistent antifungal treatment protocol. Furthermore, there
might be a possibility of bias, as patients with strictures
received more endoscopic interventions and subsequent
bile samples compared with patients without dominant
strictures. Nevertheless, since all the patients showed
comparable baseline characteristics, and the frequencies
of the endoscopic dilatation therapy and antifungal
Table 4 Risk factors of biliary candidiasis
Risk factor Univariate Multivariate
HR HR (95% CI) p-value HR HR (95% CI) p-value
Sex 1.8 0.8–4.0 0.2 1.5 0.5–4.1 0.5
Presence of dominant stenosis 0.3 0.1–1.0 0.05 0.6 0.1–2.6 0.4
Presence of IBD 1.1 0.5–2.4 0.9 0.7 0.3–2.1 0.5
Overlap with autoimmune hepatitis 1.0 0.2–4.1 0.9 0.6 0.1–6.8 0.7
Age at PSC diagnosis 1.0 1.0–1.1 0.021 1.0 1.0–1.1 0.019
Number of ERCs 1.2 1.1–1.4 0.002 1.2 1.0–1.4 0.025
Mayo Risk Score 0.9 0.7–1.3 0.7 0.9 0.6–1.3 0.6
HR, hazard ratio; CI, confidence interval; ERC, endoscopic retrograde cholangiography; IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis;
AIHOLS, autoimmune hepatitis overlap syndrome; DS, dominant stenosis.
The data show prospective factors predicting the development of biliary candidiasis. In the univariate analysis, the presence of dominant stenosis, number of
ERCs, and age at diagnosis of PSC were associated with biliary candidiasis. In the multivariate analysis, only the number of ERCs and age at diagnosis of PSC
reached significance (p < 0.05, bold).
Table 5 Risk factors of reduced transplantation-free survival
Risk factor Univariate Multivariate
HR HR (CI 95%) p-value HR HR (CI 95%) p-value
Sex 0.8 0.4–1.6 0.5 1.2 0.5–2.6 0.7
Presence of dominant stenosis 0.5 0.2–1.0 0.06 0.4 0.1–1.0 0.04
Presence of IBD 0.5 0.2–1.1 0.07 0.3 0.1–0.8 0.02
Overlap with autoimmune hepatitis 0.9 0.3–2.8 0.8 0.4 0.1–1.5 0.2
Age at PSC diagnosis 1.0 1.0–1.1 0.3 1.0 1.0–1.1 0.09
Number of ERCs 1.0 0.9–1.1 0.8 1.0 0.9–1.1 0.7
Mayo Risk Score 1.3 1.1–1.7 0.02 1.4 1.1–1.8 0.01
Candida 0.4 0.2–0.8 0.006 0.4 0.2–0.8 0.008
HR, hazard ratio; CI, confidence interval; ERC, endoscopic retrograde cholangiography; IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis;
AIHOLS, autoimmune hepatitis overlap syndrome; DS, dominant stenosis.
The data show prospective factors predictive of longer actuarial transplantation-free survival. In the univariate analysis, the presence of dominant stenosis, number
of ERCs, and age at diagnosis of PSC were associated with biliary candidiasis. In the multivariate analysis, only the number of ERCs and age at diagnosis of PSC
reached significance (p < 0.05, bold).
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therapy were equal between the subgroups, we believe
that the main conclusions of this study are reliable, and
antifungal therapy should be considered for all patients
with biliary candidiasis.
Conclusion
In conclusion, we identified persistent biliary candidiasis
as an independent risk factor of reduced transplantation-
free survival in PSC patients. Clearance of biliary Candida
results in improved survival, which is comparable to that
of patients without fungobilia. Therefore, we recommend
performing routine bile aspirations during ERC, followed
by microbial analyses, including screening for fungal spe-
cies. An aggressive antifungal treatment should be con-
ducted if fungal pathogens are identified in these patients.
Larger, prospectively designed studies are needed to con-
firm the beneficial effect of antifungal treatment in PSC
patients.
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